Effect of Cosopt Versus Combigan on Retinal Vascular Autoregulation in Primary Open Angle Glaucoma (POAG)

Mass Eye and Ear logo

Mass Eye and Ear

Status

Completed

Conditions

Glaucoma

Treatments

Drug: Dorzolamide 2%-timolol 0.5%
Drug: Brimonidine 0.2%-0.5% timolol 0.5

Study type

Interventional

Funder types

Other

Identifiers

NCT00824824
08-12-057

Details and patient eligibility

About

We have completed a study in which we examined the response of the retinal circulation to changes in posture from sitting to lying down in patients with primary open angle glaucoma (POAG). This alteration in position produces changes in the local blood pressure at the entrance to the retinal vasculature. In a healthy retina, the vasculature adapts by dilating and constricting in order to maintain a steady blood flow rate. In an eye with POAG, this often does not occur. As a result, there are large fluctuations in blood flow which may produce the retinal neuronal damage associated with glaucoma. The purpose of this study is to demonstrate that topical anti-glaucoma treatments with agents that have vasoactive as well as IOP-lowering effects can have a beneficial effect on maintaining a steady retinal blood flow rate even when there are changes in local blood pressure.

Enrollment

21 patients

Sex

All

Ages

40 to 80 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • POAG
  • Age 40 to 80 years
  • Untreated IOP greater than 21 mm Hg

Exclusion criteria

  • More than two IOP lowering medications
  • Exfoliation or pigment dispersion syndrome
  • Diabetic retinopathy
  • History of ocular surgery

Trial design

Primary purpose

Basic Science

Allocation

Randomized

Interventional model

Single Group Assignment

Masking

Quadruple Blind

21 participants in 2 patient groups

Brimonidine 0.2%-timolol 0.5% arm
Experimental group
Description:
Patients using timolol were switched to brimonidine tartrate / timolol maleate 0.2%/05% 1 get BID OU for six weeks.
Treatment:
Drug: Brimonidine 0.2%-0.5% timolol 0.5
Dorzolamide 2%-timolol 0.5% arm
Active Comparator group
Description:
Patients using timolol were switched ti dorzolamide hydrochloride / timolol 0.5% 2%/0.5% bid OU for six weeks
Treatment:
Drug: Dorzolamide 2%-timolol 0.5%

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems